GlobeNewswire·May 13, 2026, 4:30 PM ET

Prestige Consumer Healthcare Inc. Reports Fiscal 2026 Results, Announces Acquisition of LaCorium Health

PBH

Prestige Consumer Healthcare reported Q4 2026 revenues of $281.6 million & fiscal year 2026 revenues of $1,088.7 million.
Diluted EPS for fiscal 2026 was $3.91, while Adjusted Diluted EPS reached $4.38.
The company announced an agreement to acquire LaCorium Health, a leader in Australian therapeutic skin care, for approximately $150 million in cash.
LaCorium generated ~$40 million in trailing twelve-month revenue through February 28, 2026, & is expected to contribute ~$12 million in EBITDA post-integration.
Fiscal 2027 organic revenue growth outlook is set at 1% to 3%, excluding acquisition impacts.
Fiscal 2027 adjusted diluted EPS is projected between $4.42 & $4.51, with free cash flow expected to be $250 million or more.
Q4 2026 revenue decreased 5.0% year-over-year, driven by limited supply of Clear Eyes® & shipping disruptions in the Middle East.
Fiscal 2026 net cash provided by operating activities was $257.6 million, with non-GAAP free cash flow at $246.4 million.
The company opportunistically repurchased 2.3 million shares for approximately $156 million during fiscal 2026.
Net debt position as of March 31, 2026, was approximately $0.9 billion, resulting in a leverage ratio of 2.6x.
North American OTC Healthcare segment revenues for fiscal 2026 were $913.6 million, down from $960.0 million in the prior year.
International OTC Healthcare segment revenues for fiscal 2026 were $175.1 million, slightly lower than the prior year due to shipping disruptions & lower eye care sales.
Adjustments to fiscal 2026 net income included costs for the Pillar5 sterile eye care facility optimization, supplier loan write-offs, & acquisition-related expenses.
The company expects to close the Breathe Right® acquisition in June 2026 & the LaCorium acquisition in July 2026.
Medium-term outlook targets a 10% annual revenue CAGR & an 8% EPS growth CAGR over the next three years.